- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Inavolisib, Bevacizumab, Cetuximab, Atezolizumab, Tiragolumab, SY-5609, Divarasib, FOLFOX, FOLFIRI, FoundationOne®Liquid CDx
- Drug · Diagnostic Test
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Participants
- Interventions
- Digoxin, Divarasib, Rosuvastatin
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Divarasib, Pembrolizumab, Nivolumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Clovis, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
- Drug · Procedure
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 38
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 28 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 16
- States / cities
- Duarte, California • Huntington Beach, California • Irvine, California + 12 more
- Conditions
- Hepatic Impairment
- Interventions
- Divarasib
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 4
- States / cities
- Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
- Conditions
- Healthy Participants
- Interventions
- Divarasib, Itraconazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Solid Tumors
- Interventions
- Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Inavolisib, Belvarafenib, Pralsetinib, Divarasib, Camonsertib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 920 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2032
- U.S. locations
- 32
- States / cities
- Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more
- Conditions
- Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
- Interventions
- Divarasib, Sotorasib, Adagrasib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Gilbert, Arizona • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Healthy Participants
- Interventions
- Divarasib, Rifampin
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
- Interventions
- Divarasib, Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 55
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Clovis, California + 52 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 12
- States / cities
- Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more